TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22584456
Drug: Adjunctive telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive telephone coaching and electronic contact (ATC) with the Loozit group program (n=73)
Study: 21414746
Drug: Metal-backed modular
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metal-backed modular version of the implant
Study: 16761192
Drug: Rilmenidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine (0.5 mg)
Study: 9339113
Drug: IVIG (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (500 mg/kg for >1500 g, 700 mg/kg for <1500 g) on days 1, 2, and 8
Study: 29661678
Drug: Propofol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.5 mg kg‐1; group PP)
Study: 29661678
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (1.3 mg kg‐1 minute‐1; group SI)
Study: 19020919
Drug: Antioxidants (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (600 mg vitamin E and 1,000 mg vitamin C daily)
Study: 15480278
Drug: Methotrexate-mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate-mifepristone (600 mg given orally)
Study: 15480278
Drug: Methotrexate-mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate-mifepristone (600 mg given orally) with progesterone level 10 ng/l
Study: 15480278
Drug: Methotrexate-placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate-placebo with progesterone level 10 ng/l
Study: 9636863
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with fluconazole (200 mg once a day for 2 months) and flucytosine (150 mg/(kg.d) for the first 2 weeks)
Study: 9636863
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with fluconazole and flucytosine
Study: 9636863
Drug: Fluconazole monotherapy
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole monotherapy (200 mg once a day for 2 months)
Study: 3363288
Drug: Single intraduodenal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraduodenal dose of camostate
Study: 3363288
Drug: Daily ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ingestion of camostate for 5 days
Study: 435882
Drug: Chenic acid
Normalized name: Chenic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenic acid (14‐16 mg/kg/day) administered at bedtime
Study: 435882
Drug: Chenic acid
Normalized name: Chenic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenic acid (14‐16 mg/kg/day) administered in the morning
Study: 435882
Drug: Chenic acid
Normalized name: Chenic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenic acid (14‐16 mg/kg/day) administered at mealtimes
Study: 30351172
Drug: Combined RM
Normalized name: morphine sulfate Rectal Suppository [RMS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined RM + Relaxation Lighting (RM+L)
Study: 30351172
Drug: Combined Music
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Music + Relaxation Lighting (M+L)
Study: 28291511
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine (2 mg/mL)
Study: 28291511
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine (2 mg/mL) with morphine (1 mg/mL)
Study: 23603619
Drug: Low-volume strength
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume strength training (1 set, twice weekly for 13 weeks)
Study: 23603619
Drug: High-volume strength
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume strength training (3 sets, twice weekly for 13 weeks)
Study: 11500288
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of open-ended test questions by computer
Study: 11500288
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of open-ended test questions by paper-and-pencil
Study: 9929147
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with external dose > 60 Gy
Study: 7880702
Drug: suxamethonium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 0.5 mg kg‐1
Study: 7917735
Drug: suxamethonium 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 3.0 mg kg‐1
Study: 31023863
Drug: 80 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/m2 solvent-based paclitaxel (PACL80/w)
Study: 31023863
Drug: 100 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/m2 nab-paclitaxel (NAB100/w)
Study: 31023863
Drug: 150 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/m2 nab-paclitaxel (NAB150/w)
Study: 31023863
Drug: 150 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/m2 nab-paclitaxel (NAB150/2w)
Study: 24303975
Drug: Levocetirizine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine (5 mg once daily)
Study: 21142269
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of paroxetine and itraconazole
Study: 16707412
Drug: Liquid etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liquid etanercept (50 mg/mL)
Study: 16707412
Drug: Reconstituted lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted lyophilized etanercept (25 mg/mL)
Study: 12702524
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (cisplatin 25 mg/m(2) day 1, weekly for 9 weeks, irinotecan 90 mg/m(2) day 1, on weeks 1, 3, 5, 7 and 9, etoposide 60 mg/m(2) days 1‐3, on weeks 2, 4, 6, 8)
Study: 12702524
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (cisplatin 60 mg/m(2) day 1, irinotecan 60 mg/m(2) days 1, 8, 15, etoposide 50 mg/m(2) days 1‐3, every 4 weeks for four cycles)
Study: 4057034
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg intramuscularly as a pre-anesthetic
Study: 29985964
Drug: Postnatal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postnatal dexamethasone treatment
Study: 24803825
Drug: Radiotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy alone (non-drug group)
Study: 22044195
Drug: Pomegranate Seed
Normalized name: pomegranate seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate Seed Oil (PSO) 400 mg capsules twice daily for 4 weeks
Study: 22044195
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules twice daily for 4 weeks
Study: 20488410
Drug: Nonoverlapping drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoverlapping drug-eluting stents (DES)
Study: 20488410
Drug: Overlap segments
Normalized name: Seglentis
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Overlap segments of drug-eluting stents (DES)
Study: 18630591
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment with 'Xiusanzhen' technique.
Study: 18630591
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Duxil, 40 mg/time, 2 times/d for 10 weeks).
Study: 15951469
Drug: Body surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body surface area-based dosing
Study: 10715370
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tamoxifen twice daily for 1 day followed by 800 micrograms of saline‐moistened misoprostol vaginally
Study: 10715370
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 1 day followed by 800 micrograms of saline‐moistened misoprostol vaginally
Study: 10715370
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tamoxifen
Study: 10715370
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tamoxifen and misoprostol
Study: 1952856
Drug: Ciprofloxacin, 500
Normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 500 mg every 12 h orally for 7 to 10 days
Study: 1952856
Drug: Parenteral aminoglycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral aminoglycoside for 7 to 10 days
Study: 7064026
Drug: Atropine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.6 mg after metoclopramide
Study: 7064026
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg after atropine
Study: 26905985
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of magnesium sulphate intravenously
Study: 22269160
Drug: Memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (20 mg/day after up-titration over 4 weeks)
Study: 22269160
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not treated with acetyl cholinesterase inhibitors (AChEIs)
Study: 20680188
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg/d for 4 weeks
Study: 18522664
Drug: QI-Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: QI-Therapy
Study: 17632164
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dutasteride daily
Study: 2229286
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg/day; n = 7)
Study: 860743
Drug: Sensory integrative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory integrative therapy
Study: 29183393
Drug: Prophylactic penehyclidine
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic penehyclidine inhalation
Study: 29183393
Drug: Placebo (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (water for injection)
Study: 26380437
Drug: Qingyuan Shenghua
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingyuan Shenghua Decoction (QSD), one dose per day for 1 week
Study: 24377215
Drug: Chen's needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chen's needling therapy
Study: 24377215
Drug: Conventional needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional needling therapy
Study: 24377215
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between Chen's needling therapy and Conventional needling therapy
Study: 8039530
Drug: MK-0434 (0.1-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0434 (0.1-100 mg)
Study: 1002100
Drug: Contrapect (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrapect (new antitussive principle)
Study: 28528395
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of fractional CO2 laser therapy and hair growth factors
Study: 16541115
Drug: Tadalafil treatment
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil treatment
Study: 19344226
Drug: Lower SHBG
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower SHBG (Sex Hormone-Binding Globulin)
Study: 9492508
Drug: Low flow
Normalized name: high mallow flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow anesthesia (group L): oxygen 0.5 l.min‐1, nitrous oxide 0.5 l.min‐1, isoflurane
Study: 9492508
Drug: Standard flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard flow anesthesia (group H): oxygen 2 l.min‐1, nitrous oxide 4 l.min‐1, isoflurane
Study: 4204790
Drug: 3200 IU
Normalized name: sodium chloride 3200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3200 IU of vitamin E daily
Study: 4204790
Drug: Regular daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular daily dose of vitamin E (400 to 2400 IU)
Study: 24577164
Drug: Bevacizumab added
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab added to chemotherapy
Study: 24637997
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy alone
Study: 23741997
Drug: SRP+topical gaseous
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP+topical gaseous ozone
Study: 21273939
Drug: HPV‐16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV‐16/18 vaccine administered according to the alternative schedule (0‐1‐12 months)
Study: 21273939
Drug: HPV‐16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV‐16/18 vaccine administered according to the standard schedule (0‐1‐6 months)
Study: 11913307
Drug: Experimental gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental gum formulations
Study: 9286747
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements (mean calcium dose: 1050 mg)
Study: 7950469
Drug: Educational sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational sessions for physicians to standardize knowledge of the recommendations of the Canadian Hypertension Society on hypertension treatment and specific operational incentives to improve hypertension control.
Study: 2438648
Drug: 4 ABVD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ABVD chemotherapy
Study: 28718232
Drug: Intravenous steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous steroids (120 mg of injection Depomedrol) administered 1 hour before surgery
Study: 28718232
Drug: Conventional MRM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional MRM without steroids (Group A)
Study: 23843375
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) protocol consisting of myofascial release to the thoracic inlet, the splenic pump, and the pedal lymphatic pump for 6 minutes.
Study: 23843375
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) protocol
Study: 21926038
Drug: Cryosurgery during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryosurgery during daily imiquimod application (Arm I)
Study: 11533366
Drug: Montelukast 4
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4 mg chewable tablet
Study: 9506726
Drug: Levothyroxine (L‐T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L‐T4) suppressive therapy
Study: 8172437
Drug: Fluconazole, 150
Normalized name: Fluconazole, 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole, 150 mg, once daily
Study: 8172437
Drug: Oral amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amphotericin B, 500 mg every 6 hours
Study: 31072385
Drug: Compliant regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliant regular users (C-RU) of advanced PAP therapy
Study: 31072385
Drug: Subthreshold users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subthreshold users (SC-RU) of advanced PAP therapy
Study: 31072385
Drug: Noncompliant users
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Noncompliant users (NC-MU) of advanced PAP therapy
Study: 31072385
Drug: Hours of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hours of weekly PAP use
Study: 30066463
Drug: 6-month support
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month support programme consisting of psychoeducation, social support, and behavioural cognitive therapy
Study: 25141110
Drug: 1.0 W/cm2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 W/cm2 continuous ultrasound treatment
Study: 25141110
Drug: 1.0 W/cm2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 W/cm2 1:4 pulsed ultrasound treatment
Study: 25141110
Drug: 0 W/cm2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 W/cm2 ultrasound treatment (placebo)
Study: 21707451
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation, 2 g/day for 15 days
Study: 18973889
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive containing ethinyl estradiol and drospirenone for three cycles
Study: 16395988
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine in combination with oral antidiabetic drugs (OADs)
Study: 16395988
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus OADs
Study: 8594942
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion (2 pmol.kg‐1.min‐1 for 2 h)
Study: 2242369
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of salbutamol orally 30 min before vaginal administration of 2 mg prostaglandin E2 gel
Study: 2242369
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally 30 min before vaginal administration of 2 mg prostaglandin E2 gel
Study: 2242369
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of salbutamol
Study: 15277410
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin aspart every hour (SC-1h)
Study: 15277410
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin aspart every 2 hours (SC-2h)
Study: 15277410
Drug: Intravenous regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regular insulin (IV)
Study: 9205509
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg terbinafine daily for 6 weeks
Study: 8763463
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg terbinafine daily for 12 weeks
Study: 9205509
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg terbinafine daily for 6 weeks (in patients with fingernail infection)
Study: 22854553
Drug: A-solution (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-solution (oral gargling with blended essential oils diluted with distilled water)
Study: 7250591
Drug: Digoxin (0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.375 mg/day)
Study: 7250591
Drug: Beta-methyldigoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-methyldigoxin (0.25 mg/day)
Study: 27980008
Drug: Arhalofenate 800
Normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arhalofenate 800 mg + Febuxostat 80 mg
Study: 27980008
Drug: Arhalofenate 600
Normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arhalofenate 600 mg + Febuxostat 80 mg
Study: 27980008
Drug: Arhalofenate 800
Normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arhalofenate 800 mg + Febuxostat 40 mg
Study: 27980008
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Arhalofenate and Febuxostat
Study: 20963840
Drug: Azithromycin 10
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 10 mg/kg/day for 7 days followed by 5 mg/kg/day for a maximum of 6 weeks
Study: 18320254
Drug: Genetically modified
Normalized name: Genetically modified virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically modified potatoes (3 mg zeaxanthin)
Study: 18320254
Drug: Wild-type control
Normalized name: Influenza A virus A/Brisbane/10/2010 (H1N1) wild type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wild-type control potatoes (0.14 mg zeaxanthin)
Study: 16233990
Drug: Lacto-ovo-vegetarian diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacto-ovo-vegetarian diet (32 treatment sessions over 12 months)
Study: 9198292
Drug: nizatidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine (2 x 150 mg twice daily), amoxicillin (2 x 250 mg four times daily), clarithromycin (2 x 250 mg three times daily) for two weeks (niz-amox-clar group, N = 25)
Study: 9198292
Drug: omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole (20 mg twice daily), clarithromycin (2 x 250 mg three times daily) for two weeks (ome-clar group, N = 25)
Study: 9198292
Drug: bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bismuth subsalicylate (300 mg four times daily), amoxicillin (2 x 250 mg four times daily), metronidazole (250 mg four times daily) for two weeks (triple therapy group, N = 25)
Study: 4085468
Drug: Digby‐Leigh valve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digby‐Leigh valve with inspiratory resistance of 7 cmH2O l‐1s and high expiratory resistance of 25 cmH2O l‐1s (DLS)
Study: 4085468
Drug: Inspiratory resistive
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory resistive load of 12 cmH2O l‐1s (IRS1)
Study: 4085468
Drug: Inspiratory resistive
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory resistive load of 25 cmH2O l‐1s (IRS2)